VivoSeq
Psychiatry

Schizoaffective Disorder

66

Pipeline Programs↗

2

Active Trials↗

28

Companies Involved↗

Schizoaffective Disorder is a moderately active landscape with 66 programs across 28 companies. The most active players are Luye Pharma Group Ltd., Lundbeck, Neurocrine Biosciences. 19 therapies are approved with 17 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

63/100

Pipeline Velocity

11/100

Mech. Concentration

10/100

Completion Rate

89/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Luye Pharma Group Ltd. logo

Luye Pharma Group Ltd.

2 programs

Phase 1Lundbeck logo

Lundbeck

1 program

Phase 1Neurocrine Biosciences logo

Neurocrine Biosciences

1 program

Phase 2R

Reviva Pharmaceuticals

1 program

Phase 2BioMarin Pharmaceutical logo

BioMarin Pharmaceutical

1 program

Phase 2Roche logo

Roche

3 programs

Phase 2

Pipeline

Programs by Phase

Preclinical7

Ziprasidone

Pfizer

Amisulpride

Acacia Pharma Ltd

Antipsychotic Drugs

Johnson & Johnson

Haloperidol Decanoate

Wim Janssens

Olanzapine and Melatonin

Seattle Institute for Biomedical and Clinical Research

Phase 115

Dexmedetomidine Hydrochloride

Pfizer

Topiramate

Wim Janssens

Moxifloxacin

Bayer

Lumateperone

Intra-Cellular Therapies, Inc.

Divalproex Sodium ER

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 28

Sulforaphane

Eastern Cooperative Oncology Group

RP5063

Reviva Pharmaceuticals

Modafinil

Nuvo Research GmbH

NBI-98854

Neurocrine Biosciences

RO6889450

Roche

Phase 317

Raloxifene

Eli Lilly

Paliperidone

Wim Janssens

Fenretinide

Eastern Cooperative Oncology Group

Pramipexole

Boehringer Ingelheim

Varenicline

Prism Pharmaceuticals

Approved19

Risperidone

Wim Janssens

Cannabidiol

Jazz Pharmaceuticals

Olanzapine

MODAG GmbH

Midazolam

Conrado Roberto Hoffmann Filho

Clozapine

Life Extension Foundation Inc.

Analysis

Trial Status

85

clinical trials

Completed71 · 84%
Terminated5 · 6%
Withdrawn4 · 5%
Unknown status3 · 4%
Recruiting1 · 1%
Not yet recruiting1 · 1%

Clinical Trials

Trial Activity

85 trials

The Effect of Structured Medical Nutrition Therapy on Systemic Inflammation Index in Patients With Schizophrenia Receiving Antipsychotic Therapy
Recruiting·DDINA KEUMALA SARI·Preclinical·NCT07696000·100 enrolled
A User-Informed Digital Therapeutic for Specific Cognitive Disabilities to Improve Mental Health in Schizophrenia and Related Mental Illnesses
Not yet recruiting·UUniversity of Alabama at Birmingham·Preclinical·NCT07674914·45 enrolled
RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
Completed·RReviva Pharmaceuticals·Phase 2·NCT01490086·234 enrolled
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
Completed·—·Phase 3·NCT00212784·1,225 enrolled
Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder
Completed·Otsuka logoOtsuka·Phase 3·NCT00095524·300 enrolled
Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logoJohnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00412373·307 enrolled
A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
Completed·Roche logoRoche·Phase 2·NCT04512066·287 enrolled
A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937)
Completed·—·Phase 2·NCT01101464·8 enrolled
A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logoJohnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00236457·629 enrolled
A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
Completed·AAlkermes, Inc.·Phase 1·NCT02636842·47 enrolled
Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder
Completed·Pfizer logoPfizer·Phase 3·NCT00644969·128 enrolled
Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder
Completed·NNorthwestern University·Phase 4·NCT00373672·58 enrolled
A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00649064·46 enrolled
Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder
Completed·IIcahn School of Medicine at Mount Sinai·N/A·NCT01658150·11 enrolled
Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin
Completed·UUniversity of Pittsburgh·Phase 4·NCT00177580·72 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)